Condition Deep-Dives 11 min read·Updated 22 July 2026 Clinician-reviewed

Aminoglycoside Nephrotoxicity

A UK Consultant Nephrologist on gentamicin, amikacin and tobramycin — when to use them, how to dose by the Hartford nomogram, and how to keep the kidneys (and ears) safe.

  • Clinically Reviewed
  • NHS & NICE Aligned
  • UK Evidence-Based
  • Last Reviewed 22 July 2026

Professor Mohammed Mahdi Althaf

Consultant Nephrologist & Acute Physician

View Credentials

Professor Mohammed Mahdi Althaf

MD, MSc, PgDip (Clin Ed), FRCP, FHEA, FASN

Consultant Nephrologist & Acute Physician · GMC 7216325

View profile →

Direct answer

Aminoglycoside-induced proximal tubular injury — non-oliguric AKI at 5–10 days. Prevent with once-daily extended-interval dosing, short courses, euvolaemia and trough monitoring. Stop early if creatinine rises. Screen for MT-RNR1 m.1555A>G mutation to prevent profound deafness.

Key recommendation: Non-oliguric AKI at day 5–10.

Quick answer

✓ Best choices

  • Adequate fluids once your team confirms it is safe (often 1.5–2 L/day)
  • Easily digested, nutrient-dense meals during recovery
  • Vegetables, fruit, oats and whole grains as appetite returns
  • Protein in modest portions — typically 0.8–1.0 g/kg/day unless advised otherwise

✓ Foods to limit

  • NSAIDs (ibuprofen, naproxen, diclofenac) — they are nephrotoxic
  • Very salty, processed or ultra-processed foods
  • Alcohol while bloods are still recovering

Key takeaway

Aminoglycoside-induced proximal tubular injury — non-oliguric AKI at 5–10 days. Prevent with once-daily extended-interval dosing, short courses, euvolaemia and trough monitoring. Stop early if creatinine rises. Screen for MT-RNR1 m.1555A>G mutation to prevent profound deafness.

Who should be cautious

People on dialysis, post-transplant, pregnant or breastfeeding, or taking prescription medication — confirm with your renal team before changes.

Aminoglycoside Nephrotoxicity

Pharmacology & mechanism

Agents

  • Gentamicin — workhorse for Gram-negative sepsis, endocarditis, neonatal sepsis
  • Amikacin — broad-spectrum, used for MDR organisms, mycobacteria
  • Tobramycin — Pseudomonas (cystic fibrosis), nebulised + IV
  • Streptomycin — TB, plague, tularaemia
  • Neomycin — oral only (hepatic encephalopathy); not absorbed

Pharmacokinetics

  • Concentration-dependent killing → high peaks more effective
  • Post-antibiotic effect → trough can be low
  • Renally excreted unchanged → dose by eGFR
  • Synergistic with beta-lactams in endocarditis

Nephrotoxic Mechanism

  • Megalin-mediated endocytosis at proximal tubular brush border
  • Lysosomal accumulation → phospholipidosis
  • Mitochondrial injury → ATP depletion
  • Cell apoptosis/necrosis
  • Saturation kinetics — toxicity REDUCED by extended-interval dosing (fewer toxic peaks)

Ototoxic Mechanism

  • Cochlear hair cell death (high-frequency loss first; can progress to profound deafness)
  • Vestibular hair cell death (oscillopsia, ataxia)
  • MT-RNR1 m.1555A>G mutation predisposes to ototoxicity at first dose

Clinical features & risk factors

Presentation

  • Non-oliguric AKI 5–10 days into therapy
  • Creatinine rises gradually
  • Hypokalaemia, hypomagnesaemia (renal wasting)
  • Hypocalcaemia (Mg-dependent)
  • Urine: granular casts, tubular cells, mild proteinuria
  • Polyuria from concentrating defect
  • Less commonly Fanconi syndrome features

Risk Factors

  • Older age
  • Pre-existing CKD
  • Dehydration / hypotension
  • Duration > 7 days
  • High cumulative dose
  • Concurrent nephrotoxins (NSAIDs, vancomycin, contrast, amphotericin, cisplatin, loop diuretics, ACE-i/ARB if hypovolaemic)
  • Sepsis / shock
  • Liver disease
  • Hypoalbuminaemia

Monitoring

  • Baseline U&E, weight, eGFR
  • Daily U&E during therapy
  • Mg, Ca, PO4
  • Aminoglycoside levels per local policy
  • Hearing assessment if > 7 days or symptoms

Prevention & management

DOSING (extended-interval, Hartford nomogram):

  • Gentamicin/tobramycin: 5–7 mg/kg q24h
  • Amikacin: 15 mg/kg q24h
  • Use ADJUSTED body weight if BMI > 30
  • eGFR > 60: q24h
  • eGFR 40–60: q36h
  • eGFR 20–40: q48h
  • eGFR < 20: single dose, then level-guided
  • Plot 6–14 h post-dose level on Hartford nomogram → next interval
  • Pre-dose (trough) must be UNDETECTABLE (< 1 mg/L for gentamicin)
  • Synergistic endocarditis dosing: 1 mg/kg q8h (different monitoring)

Safe Prescribing (Npsa / Mhra)

  • Limit to 5–7 days where possible
  • Avoid concurrent nephrotoxins
  • Maintain euvolaemia
  • Daily creatinine
  • Stop / change antibiotic if creatinine rises > 50% or > 26 µmol/L
  • Audiology baseline + at end of treatment if > 7 days
  • Screen for MT-RNR1 m.1555A>G in patients with maternal family history of aminoglycoside-induced deafness (MHRA Drug Safety Update 2023)
  • Document indication, dose, course duration, audiology consent

When AKI Occurs

  • Stop aminoglycoside immediately
  • Switch to alternative (per sensitivities)
  • Maintain hydration
  • Replace K, Mg, Ca
  • Monitor recovery — usually within 2–3 weeks
  • Permanent CKD in a minority
  • Avoid further aminoglycosides if possible

Nebulised Tobramycin (Cf)

  • Minimal systemic absorption; nephrotoxicity rare
  • Still monitor renal function periodically
Acute Tubular Necrosis (ATN)
Related reading: Acute Tubular Necrosis (ATN).

Key practical tips

Designed for quick scanning — what to order, what to avoid, sensible portions, common mistakes.

  • Follow the NHS sick-day rules: stop ACE inhibitors, ARBs, NSAIDs and diuretics when dehydrated
  • Re-check eGFR at 3 and 6 months as NICE recommends
  • Tell every clinician you see that you have had AKI

Clinical guidance

TL;DR summary

Aminoglycoside-induced proximal tubular injury — non-oliguric AKI at 5–10 days. Prevent with once-daily extended-interval dosing, short courses, euvolaemia and trough monitoring. Stop early if creatinine rises. Screen for MT-RNR1 m.1555A>G mutation to prevent profound deafness.

Key takeaways
  • Non-oliguric AKI at day 5–10.
  • Use once-daily dosing (Hartford) where possible.
  • Trough must be undetectable before next dose.
  • Avoid concurrent nephrotoxins.
  • Test MT-RNR1 m.1555A>G in high-risk patients (MHRA).
Kidney Diet & Nutrition Considerations

After acute kidney injury (AKI) the priority is recovery: rehydration, treating the underlying cause, stopping nephrotoxins and giving the kidneys a calm nutritional environment. Once eGFR is recovering, a balanced Mediterranean-style diet with sensible salt, sensible protein and good hydration supports healing — and reduces the risk of AKI tipping into long-term CKD.

Foods to prioritise

  • Adequate fluids once your team confirms it is safe (often 1.5–2 L/day)
  • Easily digested, nutrient-dense meals during recovery
  • Vegetables, fruit, oats and whole grains as appetite returns
  • Protein in modest portions — typically 0.8–1.0 g/kg/day unless advised otherwise

Foods to limit

  • NSAIDs (ibuprofen, naproxen, diclofenac) — they are nephrotoxic
  • Very salty, processed or ultra-processed foods
  • Alcohol while bloods are still recovering

Potassium, phosphate and protein needs vary between individuals — please confirm personal targets with your renal team or dietitian. Browse the Kidney Diet Hub for more guides in this cluster.

Frequently asked questions

What is aminoglycoside nephrotoxicity?

Aminoglycoside antibiotics (gentamicin, amikacin, tobramycin, streptomycin, neomycin) cause non-oliguric acute kidney injury in 10–25% of treated patients. The mechanism is proximal tubular accumulation via megalin-mediated endocytosis, lysosomal phospholipidosis and mitochondrial injury. Typically presents 5–10 days into treatment with rising creatinine, magnesuria, hypokalaemia, hypocalcaemia and a urine sediment containing granular casts.

How is it prevented?

Use once-daily extended-interval dosing (gentamicin 5–7 mg/kg q24h via the Hartford nomogram) rather than multiple daily doses — fewer toxic peaks at the proximal tubular brush border. Limit course to 5–7 days where possible. Avoid concurrent nephrotoxins (NSAIDs, contrast, vancomycin, loop diuretics, ACE-i/ARB if dehydrated, amphotericin). Ensure euvolaemia. Dose-adjust for eGFR. Monitor creatinine daily and trough/post-dose levels per local protocol.

How are levels monitored?

Once-daily dosing (Hartford): pre-dose trough should be UNDETECTABLE (< 1 mg/L for gentamicin) before the next dose. Levels at 6–14 h post-dose are plotted on the Hartford nomogram to determine the next dosing interval (q24h, q36h or q48h). Multiple daily dosing (e.g. for endocarditis with synergistic dosing): trough < 1 mg/L (gentamicin) before next dose, peak 3–5 mg/L. Amikacin: trough < 5 mg/L, peak 20–30 mg/L.

What is the prognosis?

Most cases recover fully if recognised early and the drug stopped. Mortality from the AKI itself is low, but the underlying sepsis carries its own risk. Permanent loss of GFR in a minority. Cochleovestibular toxicity (irreversible deafness, oscillopsia) is the more feared complication and is unrelated to the kidney injury but shares the risk factors of duration, cumulative dose and age. UK MHRA has issued specific guidance on familial mitochondrial mutations (MT-RNR1 m.1555A>G) — ototoxicity at the very first dose; screen high-risk patients.

What should I eat to recover from acute kidney injury?

Most adults recovering from AKI do best on a balanced Mediterranean-style diet with adequate hydration (once your team confirms it's safe), moderate protein (around 0.8–1.0 g/kg/day), lower salt, and avoidance of NSAIDs. Your renal team will give you personalised fluid and protein targets based on your recovery.

Nutritional challenges in kidney disease

Many people living with kidney disease have to limit foods because of potassium, phosphate, diabetes, dialysis, appetite changes or simply the time it takes to cook from scratch every day. That can make it harder to keep daily nutrition balanced — particularly for vitamins and minerals that food alone may not fully cover.

Kidney Vitality is a UK-formulated daily nutritional support product designed by Consultant Nephrologist Professor Mohammed Mahdi Althaf with renal nutrition in mind from the start. It keeps doses moderate, leaves out added potassium, phosphate and magnesium, and avoids megadose vitamin A — sitting alongside a kidney-friendly diet, not replacing it.

Why Kidney Vitality fits this need

Built around UK guidance

Aligned with BNF 2024, MHRA Drug Safety Updates (mitochondrial mutations, ototoxicity), NPSA safe-prescribing alerts and local NHS Trust aminoglycoside protocols (Hartford-style).

Designed by a UK Consultant Nephrologist

Formulated and reviewed by Professor Mohammed Mahdi Althaf (GMC 7216325).

Practical & MHRA-aware

Practical UK guidance on Hartford dosing, monitoring and the MT-RNR1 ototoxicity warning.

Designed by a UK Consultant Nephrologist

Ready to support your kidney health?

If you have been researching kidney health, supplements, CKD nutrition or kidney-friendly living, Kidney Vitality was developed specifically around those principles by Professor Mohammed Mahdi Althaf (GMC 7216325). Developed using renal nutrition principles.

  • Designed Using Renal Nutrition Principles
  • No Added Potassium
  • No Added Phosphorus
  • UK Manufactured
  • One capsule daily
  • UK GMP — BRCGS, NSF GMP, Halal
Subscribe & Save — £20.39/monthCheck your current multivitamin

✓ Free UK tracked delivery  ·  ✓ Delivered every 30 days  ·  ✓ Pause or cancel anytime  ·  ✓ Never run out

ComparisonKidney VitalityTypical high-street multivitamin
Added potassiumNoneOften included
Added phosphateNoneOften included (E338–E452)
Vitamin A (retinol)No megadoseOften high-dose retinol
Kidney-focused formulationYesNo — general population
Consultant Nephrologist involvementYes (GMC 7216325)No
UK GMP manufacturedYes (BRCGS, NSF GMP)Varies

Food supplement. Not a medicine and not a treatment for kidney disease. Speak with your GP, pharmacist or renal team before starting any new supplement, especially in advanced CKD, on dialysis, post-transplant, pregnant or breastfeeding.

Clinical reviewer

Professor Mohammed Mahdi Althaf

Consultant Nephrologist

Acute Physician

GMC 7216325

View Full Biography

Professor Mohammed Mahdi Althaf is a UK Consultant Nephrologist and Acute Physician with a special interest in chronic kidney disease, AKI prevention and renal nutrition. He combines hospital practice with patient education and clinical guidance review.

View professional profile →
View Credentials
  • MD
  • MSc
  • PgDip (Clin Ed)
  • FRCP
  • FHEA
  • FASN

About this article

Written for UK patients and based on:

  • NICE guidance
  • NHS resources
  • British Dietetic Association guidance
  • Kidney Care UK resources
View methodology

Each article is researched against current UK clinical guidance (NICE NG203, NG118, NG136), NHS patient resources, KDIGO and KDOQI international guidelines, and the British Dietetic Association Renal Nutrition Group. Drafts are written by the Kidney Vitality editorial team and reviewed by a UK Consultant Nephrologist before publication. Content is reviewed on a rolling basis and updated when guidance changes.

Editorial standards

  • Clinically reviewed
  • NHS-aligned
  • NICE-aligned
  • Evidence-based
  • Reviewed before publication
View full editorial process

Every article is researched and written by the Kidney Vitality editorial team using current UK clinical guidance (NICE NG203, NG118, NG136), NHS patient resources, KDIGO/KDOQI international guidelines, and British Dietetic Association renal nutrition guidance. Drafts are reviewed for clinical accuracy by Professor Mohammed Mahdi Althaf, MD, MSc, PgDip (Clin Ed), FRCP, FHEA, FASN (Consultant Nephrologist & Acute Physician, GMC 7216325) before publication. Content is updated when UK guidance changes.

References (4)View Sources
  1. NICE NG203: Chronic kidney disease — assessment and management
  2. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD
  3. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update
  4. British Dietetic Association — Renal Nutrition Group

Medical disclaimer

This content is educational only and does not replace personalised medical advice.

Read full disclaimer

This page is general information, not personal medical advice. If you have chronic kidney disease, are on dialysis, have had a kidney transplant, are pregnant or breastfeeding, or take prescription medication, please confirm any supplement with your GP, pharmacist or renal team before starting.

← Back to all guides